In a regulatory filing, Acadia Pharmaceuticals (ACAD) disclosed that on January 13, the company presented at the J.P. Morgan Healthcare Conference announcing, among other things, that it anticipates 2025 net sales will exceed $1B, consistent with prior guidance.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACAD:
- Acadia Pharmaceuticals price target raised to $40 from $35 at UBS
- Acadia Pharmaceuticals price target raised to $36 from $33 at Citi
- Acadia Pharmaceuticals price target raised to $34 from $29 at Needham
- Acadia Pharmaceuticals price target raised to $37 from $32 at H.C. Wainwright
- Acadia Pharmaceuticals announces FDA approval of Daybue Stix for oral solution